EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era

Tânia Lapão, Rui Barata, Cristina Jorge, Carlos Flores, Joaquim Calado

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26031121 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Tânia Lapão und 4 weiteren Autor:innen. Beteiligte Einrichtung: Unidade Local de Saúde São José, Serviço de Patologia Clínica, Centro Clínico Académico de Lisboa, 1150-199 Lisboa, Portugal. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant, Tolvaptan, Biomarkers, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centro Hospitalar de Lisboa Central, Fundo de Financiamento da Investigação da ULS São José.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the approval of tolvaptan as the first specific medicine for the treatment of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD), biomarker discovery has gained renewed interest as it is widely recognized that these will be crucial in clinical decision-making, serving as either prognostic or predictive tools. Since the marketing authorization was first issued in 2015 for ADPKD, tolvaptan has remained the sole pharmacological compound specifically targeting the disease. For ADPKD patients it is an invaluable medicine for retarding disease progression. Although the field of overall biomarker discovery and validation has been detailed in several publications, the role of inflammation remains largely overlooked in ADPKD. The current work aims to provide the reader with an updated review of inflammation biomarkers research in ADPKD, highlighting the role of urinary MCP-1 (monocyte chemoattractant protein-1) as the most promising tool.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Kidney, Autosomal DominantTolvaptanBiomarkersInflammationAntidiuretic Hormone Receptor AntagonistsHumansChemokine CCL2Animals

Stichwörter der Autor:innen

ADPKDgeneinflammationkidneytolvaptan

Substanzen

TolvaptanBiomarkersChemokine CCL2Antidiuretic Hormone Receptor AntagonistsCCL2 protein, human

Autor:innen und Institutionen

  • Unidade Local de Saúde São José, Serviço de Patologia Clínica, Centro Clínico Académico de Lisboa, 1150-199 Lisboa, Portugal.
  • ToxOmics, NOVA Medical School, Universidade Nova de Lisboa, 1150-082 Lisbon, Portugal.
  • Unidade Local de Saúde São José, Serviço de Nefrologia, Centro Clínico Académico de Lisboa, 1069-166 Lisboa, Portugal.

Förderung

  • Centro Hospitalar de Lisboa Central
  • Fundo de Financiamento da Investigação da ULS São José

Zitieren

APA

Lapão, T., Barata, R., Jorge, C., Flores, C., & Calado, J. (2025). Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26031121

Vancouver

Lapão T, Barata R, Jorge C, Flores C, Calado J. Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26031121

BibTeX
@article{Lapo2025,
  author = {Lapão, Tânia and Barata, Rui and Jorge, Cristina and Flores, Carlos and Calado, Joaquim},
  title = {Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26031121}
}
Kostenlos starten →